The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
As stated in the WHO report, "essential medicines are those that satisfy the priority health care needs of a population. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
MADRID -- Businesswire -- The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines[1].
This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%. This was evidenced by the SECURE[2] study, with results published in August 2022 in the New England Journal of Medicine[3] (NEJM).
“The SECURE results showed, for the first time, that the cardiovascular polypill developed by the CNIC and Ferrer achieves clinically relevant reductions in recurrent cardiovascular events in patients who have suffered a myocardial infarction,” said Dr. Valentín Fuster, principal investigator of the study, General Director of the CNIC, President of Mount Sinai Heart and Physician-in-Chief of Mount Sinai Hospital, New York.
As stated in the WHO report, “essential medicines are those that satisfy the priority health care needs of a population. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford.”
According to Oscar Pérez, Chief Marketing, Market Access and Business Development Officer at Ferrer, “the 33% reduction in cardiovascular mortality demonstrates the efficacy of treatment with Trinomia[4] compared to standard treatment. The inclusion of this therapeutic solution in the WHO's List of Essential Medicines confirms our aim to make a positive impact in society and is an important step in our mission to bring significant and differential value to people with cardiovascular disease.”
Currently, the cardiovascular polypill developed by the CNIC and Ferrer is marketed in 25 countries and the feasibility of extending its distribution to additional territories, including the United States, is under analysis.
Bibliographical references:
[1] - https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
[2] - SECURE study - https://www.cnic.es/en/clinical-research
[3] - Polypill Strategy in Secondary Cardiovascular Prevention, Castellano JM, Fuster V et al. New England Journal of Medicine (NEJM). 2022 Aug. (consult: https://www.nejm.org/doi/full/10.1056/NEJMoa2208275)
[4] - Trinomia® data sheet: SUMMARY OF PRODUCT CHARACTERISTICS (https://www.ferrer.com/sites/default/files/2023-08/Trinomia_SmPC.pdf)
View source version on businesswire.com: https://www.businesswire.com/news/home/20230802658773/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Ferrer
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 헤비메탈의 거장 ‘잉베이 맘스틴’ 40주년 기념 서울 내한 공연 12월 18일 개최 - 뉴스와이어
- 현대자동차, 2025 아이오닉 5 N 출시 - 뉴스와이어
- 라이노스 ‘소음·가격’ 다 잡은 3세대 산소발생기 ‘휠리O2’ 출시 - 뉴스와이어
- ‘2024년 춘천 애니·토이 한마당’ 개최 - 뉴스와이어
- KG 모빌리티, 2024 미래 모빌리티 테크쇼 개최 - 뉴스와이어
- 오데마 피게, 로열 오크 콘셉트 컬렉션에서 새로운 단조 카본 첫 공개 - 뉴스와이어
- 숯불 함박스테이크 전문점 골드버그, SBS 생방송 투데이 출연 - 뉴스와이어
- LS일렉트릭, 베트남 ‘2024 일렉트릭에너지쇼’ 참가 - 뉴스와이어
- 미아리고개예술극장, 연극 ‘생활의 비용’ 재공연 - 뉴스와이어
- 기아, 일본 PBV 시장 진출 - 뉴스와이어